Aduhelm’s effectiveness is questionable. In a sensible move, Medicare recognizes this. Published by Jane the Actuary View all posts by Jane the Actuary
2 thoughts on “Forbes post, “Finally, Medicare Takes A Step Towards Cost-Control – And Alzheimer’s Advocates Push Back””